Summary Basis of Decision for XTANDI

Health Canada has issued a Notice of Compliance to Astellas Pharma Canada Inc. for the drug product, Xtandi. Based on Health Canada's review, the benefit/risk profile of Xtandi is favourable for the treatment of patients with metastatic castration-resistant prostate cancer in the setting of medical or surgical castration who have received docetaxel therapy. Read more here.